Consensus Alpha Tau Medical Ltd.

Equities

Delayed Nasdaq Other stock markets 12:11:45 2024-05-16 EDT			5-day change	1st Jan Change
2.7 ^USD	+1.89%		+9.31%	-10.30%

05-06	Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	CI
03-07	Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

502028.pXHLTBkgwSJUCm9n-TU2B8p72Ycvrjd3mFFlzKEmbB4.-j2NFFoVjkc4MzcBo0BUXo9Ll9NLx31BrAEkpcpUXXrmOIJ4RkeSYWBAKg~385b15aff4541c6d625edfc541a75ab4

Piper Sandler Adjusts Alpha Tau Medical's Price Target to $8 From $12, Keeps Overweight Rating	11-17	MT
HC Wainwright Starts Alpha Tau Medical at Buy With $9 Price Target	23-04-24	MT
Piper Sandler Adjusts Alpha Tau Medical's Price Target to $12 From $19, Keeps Overweight Rating	22-11-23	MT
Cantor Fitzgerald Initiates Alpha Tau Medical at Overweight with $20 Price Target	22-04-14	MT
Piper Sandler Starts Alpha Tau Medical at Overweight With $19 Price Target	22-04-08	MT
Citigroup Initiates Alpha Tau Medical at Buy With $21 Price Target	22-04-04	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.65 USD

Average target price

9.25 USD

Spread / Average Target

+249.06%

High Price Target

13 USD

Spread / Highest target

+390.57%

Low Price Target

7 USD

Spread / Lowest Target

+164.15%